S107 NEW
| Price | $32 | $58 | $88 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: S107 | CAS No.: 927871-76-9 |
| Purity: 99.63% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | S107 |
| Description | S107 is a RyR-selective 1, 4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels. |
| In vitro | S107, a small compound, enhances calstabin2 binding to RyR2 at low nanomolar concentrations and does not interact with over 400 receptors, enzymes, and ion channels at up to 10 μM. It shows no effect on cardiac ion channels, including voltage-gated Na+, K+, and Ca2+ channels, or on normal Ca2+ signaling in cells[1]. S107 is a potential candidate for treating catecholaminergic polymorphic ventricular tachycardia (CPVT), exerting antiarrhythmic effects on CPVT-hiPSC-CMs. Pre-incubation with 10 μM S107 significantly reduces the incidence of CPVT-hiPSC-CMs presenting DADs to 25% by stabilizing the closed state of ryanodine receptor 2[2]. S107 may improve skeletal muscle function by stabilizing the RyR1-FKBP12 complex, increasing FKBP12 binding to RyR1 in SR vesicles in the presence of reduced glutathione and the NO-donor NOC12 but not in the presence of oxidized glutathione. It reverses the harmful effects of redox active species on SR Ca2+ release in skeletal muscle by binding to RyR1 low affinity sites[3]. |
| In vivo | S107 effectively inhibits seizures and arrhythmias in mutant mice without blocking the channel or changing normal calcium (Ca2+) signaling; it specifically prevents leakage in the channel[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (262.77 mM) |
| Keywords | S 107 | S-107 | S107 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Anti-Diabetic Compound Library | CNS-Penetrant Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1.00/1g |
VIP6Y
|
Career Henan Chemical Co
|
2019-12-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY